Navigation Links
Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles
Date:8/27/2012

rminated Trial Analysis 495 Endpoints - Clinical Trials in Chronic Obstructive Pulmonary Disorder - Marketed and Pipeline Products Assessment 765.1 Introduction 765.2 Primary Endpoints Used in COPD Clinical Trials 805.2.1 Pulmonary Function Tests 805.2.2 Baseline Dyspnea Index and Borg-Dyspnea Score 805.2.3 Rate of Exacerbations 805.2.4 Induced Sputum Analysis 805.2.5 Biomarkers of COPD 805.3 Secondary Endpoints Used in COPD Clinical Trials 805.3.1 Exercise Endurance Time 805.3.2 Serum Hematology 805.3.3 Six Minute Walk Distance 805.3.4 Time to First Exacerbation 815.4 COPD Therapeutics – Major Marketed Drugs 815.4.1 Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder) 815.4.2 Brovana (Arformoterol) 825.4.3 Foradil Aerolizer (Formoterol Fumarate Inhalation Powder) 835.4.4 Symbicort (Budesonide/Formoterol Fumarate Dihydrate) 845.4.5 Advair Diskus (Fluticasone Propionate and Salmeterol Inhalation Powder) 855.4.6 Daxas (roflumilast) 875.5 COPD Therapeutics – Promising Drugs Under Clinical Development 885.5.1 Aclidinium Bromide 885.5.2 NVA237 (Glycopyrronium Bromide) 895.5.3 Dulera 895.6 Phase III Clinical Trial Analysis 905.6.1 Completed Trial Analysis 905.6.2 Active Trials Analysis 945.6.3 Terminated Trial Analysis 985.7 Phase II Clinical Trial Analysis 1005.7.1 Completed Trial Analysis 1005.7.2 Active Trial Analysis 1045.7.3 Terminated Trial Analysis 1076 Endpoints - Clinical Trials in Cystic Fibrosis - Marketed and Pipeline Products Assessment 1256.1 Introduction 1256.2 Primary Endpoints Used in Cystic Fibrosis Clinical Trials 1296.2.1 Coefficient of Fat Absorption 1296.2.2 Lung Microbiology 1296.2.3 Biomarkers 1296.3 Secondary Endpoints Used in Cystic Fibrosis Clinical Trials 1296.3.1 Nasal Potential Difference 1296.3.2 Sweat Chloride Concentration 1296.4 Cystic Fibrosis Therapeutics – Major Marketed Drugs 1296.4.1 Tobi (Tobramycin Inhalation Solution) 1296.4.2 Pulmozyme (Dornase Alfa) 1306.4.3 Cayston (aztreonam for Inhalation Solution) 1316
'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
2. As Tuberculosis Grows More Difficult to Control, Vaccine Candidate to Prevent Disease Enters Clinical Testing
3. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
4. VolitionRX to Begin Prospective Clinical Trial in Colon Cancer
5. Indegene Introduces TrialPedia 2.0 with Advantage Insights, Making It the Most Comprehensive Clinical Trial Analytics and Decision Support Platform for the Pharma Industry
6. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
7. AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
8. Nectid Announces Initiation Of Clinical Development Of Autism And Pain Drugs
9. Meritage Pharma Initiates Clinical Trial of Oral Budesonide Suspension for Adolescent and Adult Patients with Eosinophilic Esophagitis
10. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
11. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According ... on medical technology market intelligence, the ... and occlusion (TEO) device markets will expand moderately ... the fastest-growing segments. In particular, increasing interest in ... oncology has fueled rapid growth of these markets. ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ... per share, net to the seller in cash, without ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ... including reductions in body fat content and preserved ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Inc. (Nasdaq: ALXA ) today announced that company ... will present during the MDB Bright Lights Conference 2011.  The ... 10:00 a.m. Eastern Time.  The presentation will be webcast live ... via the Web, please go to the Investor Relations tab ...
... DIEGO, May 6, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... to present at the Bank of America Merrill Lynch 2011 Health ... Time (1:00 p.m. Eastern Time) at the Encore at the Wynn ... Ph.D., Arena,s Vice President, Lorcaserin Development, is scheduled to provide a ...
Cached Medicine Technology:Alexza to Present at the MDB Bright Lights Conference 2011 2Alexza to Present at the MDB Bright Lights Conference 2011 3Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference 2Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference 3
(Date:4/14/2014)... Therapeutics, Inc., announced today a publication demonstrating that ... human red blood cells exposed to plasma samples ... anemia (AIHA). The article entitled "TNT003, an inhibitor ... induced by cold agglutinin disease patient autoantibodies" was ... earlier this month. TNT003 is the murine analog ...
(Date:4/14/2014)... around the world, many people live and work in ... block sunlight. And as the global population continues to ... will only spread. , To alleviate the problem, ... redirects sunlight onto narrow streets and alleyways. The panel ... at an angle, where it spreads sunlight onto the ...
(Date:4/14/2014)... professor of chemical engineering at Virginia Tech , ... analyze living cells. The long-term goal is to gain ... In his lab , Lu and his students ... events inside cells. These devices promote high sensitivity and ... cells. , Based on their record of achievements, the ...
(Date:4/14/2014)... April 2014, Perth, Australia. Drug discovery company Proteomics ... development of a companion diagnostic (CDx) test with ... , The research team authenticated the panel of ... control samples. Seven biomarkers were validated at high ... , The mass spectrometry data was then cross-validated ...
(Date:4/14/2014)... guidelines for high-risk bladder cancer, chemotherapy before or ... clinical practice. The findings are published early online ... the American Cancer Society. , Clinical trials have ... muscle-invasive bladder cancer who are given chemotherapy before ... after surgery also improves survival. To investigate the ...
Breaking Medicine News(10 mins):Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Efficient analysis of small quantity of cells improves chances to understand disease 2
... /PRNewswire/ -- Aesthetic Medical Educators ... medical professionals on Aesthetic Procedures over the past ... training include physicians, nurses, physician assistants and dentists, ... in his/her practice.These medical professionals have been trained ...
... Convene in Washington D.C. ... Pass Legislation that Will Protect the Public WASHINGTON, April ... of foodborne illness, including surviving family members of those ... Capitol to share their stories, meet with legislators and ...
... -- With the 2009 NBA playoff season ... public affairs television program that tells the compelling and ... and diabetes patient Dominique Wilkins. Sharing Miracles ... stations. A nine-time NBA all-star who spent the majority ...
... Controls Limit Vaccine SuppliesDALLAS, April 29 Fears of ... new vaccines, as well as meeting public demand for ... National Center for Policy Analysis. "We are facing ... six vaccines for common childhood illnesses," said NCPA Senior ...
... Executive Chairman & CEO Douglas MacLellan offers expert insight ... April 29 AMDL Inc. ... major operations in China, announced today its Executive Chairman ... featured in The Wall Street Transcript - ...
... appear to be safe, but more research needed ... shows promise in treating diabetic polyneuropathy, a disorder that ... years, a new study finds. , Researchers in Boston ... (VEGF) gene may help patients with diabetic polyneuropathy. The ...
Cached Medicine News:Health News:Aesthetic Medical Educators Training Successfully Trains Over 2,000 Medical Professionals on Aesthetic Procedures 2Health News:Foodborne Illness Victims Mark President Obama's First 100 Days By Calling For Permanent Fix To Food Safety System 2Health News:Foodborne Illness Victims Mark President Obama's First 100 Days By Calling For Permanent Fix To Food Safety System 3Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 2Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 3Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 4Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 5Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 6Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 7Health News:'Sharing Miracles' Television Program to Feature NBA Hall-of-Famer, Scoring Champ Dominique Wilkins 8Health News:Swine Flu Outbreak Illustrates Problems in Vaccine Development 2Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 2Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 3Health News:Gene Therapy Improves Diabetic Neuropathy in Study 2
... onboard rail clamps mount ... tables and stretchers. The ... need for lifting. Easy ... stable surface combined with ...
The DHS Basic Set is available with either self-tapping or non-self-tapping screws. Either instrument set provides complete instrumentation in one graphic case for use with the Universal Implant Set,...
... is a versatile, fully powered orthopaedic and ... traction facilities, a powered centre break and ... versatile too. ,<br.,In fact the RX600 is ... it is for traction procedures. The RX600 ...
... orthopedic trauma procedures. Part of the ... trauma table top provides a complete, ... positioning and provides for skin or ... hip pinnings; femur, supine or lateral ...
Medicine Products: